Tauriga Sciences Inc (TAUG)

[Johnny_C]

Nobody stated there are guarantees as to the trial results, but I think there is a great chance to get good Phase 2 results from both the monotherapy and the adjunctive Phase 2 trials. Just getting through Phase 2 could make AV-101 a billion dollar plus asset just for depression, the drug also has great peer reviews for pain, Hodgkinson's and Parkinson's.

I hope to see results from NIMH between June and August, that could be a huge catalyst.

The best of the best is rnning the NIMH trial, per VTGN website

AV-101 is currently being evaluated in an ongoing Phase 2 monotherapy study for the treatment of MDD, a study being conducted and funded by the U.S. National Institute of Mental Health (NIMH), part of the U.S. National Institutes of Health (NIH). Dr. Carlos Zarate of the NIMH is the Principal Investigator of the study. AV-101's mechanism of action is fundamentally differentiated from all FDA-approved antidepressants and atypical antipsychotics, with potential to further drive a paradigm shift towards a new generation of safer and faster-acting antidepressants. VistaGen's development strategy for AV-101 is focused on establishing it as the primary augmentation option for individuals with MDD with inadequate response to standard antidepressants, displacing adjunctive use of atypical antipsychotics such as aripiprazole in the current depression treatment paradigm. VistaGen currently anticipates topline results of this NIMH-sponsored Phase 2 study in 2018.